




EASL	AASLD	APASL
Fibrosis can be assessed by non- invasive methods. Liver biopsy reserved for cases where there is uncertainty or potential additional aetiologies	Liver biopsy should be considered in patients with persistent borderline normal or slightly elevated ALT levels, particularly in patients over age 40 who have been infected with HBV from a young age	Biopsy if ALT persistently elevated, or with family history of HCC or cirrhosis and/or to rule out other causes of elevated ALT
	Liver stiffness measurements are more accurate than serum fibrosis panels (APRI, FIB-4)	









9


Indications for treatment	
Primarily based on the combination of 3 criteria HBV DNA and serum ALT and severity of	f liver disease
Recommendations	
Should be treated	
 HBeAg-positive or -negative chronic hepatitis B with HBV DNA > 2,000, ALT > ULN and/or m necroinflammation or fibrosis 	oderate liver
Cirrhosis, any detectable HBV DNA (regardless of ALT level)	
• HBV DNA > 20,000 IU/mL and ALT > 2 x ULN (regardless of severity of histological lesions)	
May be treated	
 HBeAg-positive chronic HBV infection >30 years old, regardless of severity of liver histology defined by persistently normal ALT and high HBV DNA levels) 	gy (HBV infection
 Can be treated HBeAg-positive or -negative chronic HBV infection and family history of HCC or cirrhosis ar manifestations, even if typical treatment indications are not fulfilled. 	nd extrahepatic

EASL CPG HBV. J Hepatol 2017;67:370-98





	HBeAg	HBeAg negative		
	Chronic infection	Chronic hepatitis	Chronic infection	Chronic hepatitis
Old terminology	Immune tolerant	Immune reactive	Inactive carrier	HBeAg- CHB
HBsAg	High	High/intermediate	Low	Intermediate
HBeAg	Positive	Positive	Negative	Negative
HBV DNA	>10 ⁷ IU/mL	104-107 IU/mL	<2000 IU/mL ⁺	>2000 IU/mL
ALT	Normal	Elevated	Normal	Elevated*
Liver disease	None/minimal	Moderate/severe	None	Moderate/severe
Treatment Indication	No	Yes	No	Yes






HBV vaccine cannot protect all babies from high viral load carrier mothers








Guidelines for stopping antiviral treatment in pregnant women on antiviral treatment

EASL 2017	AASLD 2016	APASL 2016
May be continued up to 12 weeks after delivery (Level 1, Grade 1)	Antiviral therapy was discontinued at birth to 3 months postpartum in most of the studies. With discontinuation of treatment, women should be monitored for ALT flares every 3 months for 6 months. (C1)	The NAs could be stopped at birth and when breastfeeding starts, if there is no contraindication to stopping NAs (B2)
	Te	rrault N, et al. Hepatology 2016;63:26 EASL. J Hepatol 2017;67:37 Sarin S, et al. Hepatol Int. 2016;10

Hepatitis B Virus markers Hepatitis B Virus (HBV) status Goals							
HBsAg	HBsAb	HBcAb	HBV infection	HBV ccc-DNA	Immunity for HBV	Goals title	
negative	positive	positive	no	yes	Natural immunity	 Preventing HBV infection reactivation Preventing HBV related HCC mortality 	
positive	negative	positive	yes	yes	Would not have immunity	 Preventing HBV infection reactivation Preventing HBV disease progression and fibrosis Preventing HBV related HCC mortality 	
	,			rapy candid			
	(cortio					pt, Prograf, Neoral, Immuran, mTOR	
\bigcirc		costeroid,	MTX, Anti-TNF,			pt, Prograf, Neoral, Immuran, mTOR	
2			MTX, Anti-TNF,			pt, Prograf, Neoral, Immuran, mTOR	
2	. Onco	costeroid, logy pa	MTX, Anti-TNF,	Rituximab, Tra		pt, Prograf, Neoral, Immuran, mTOR	



Risk	-Based Preventio	n of HBV Reactiv	vation	
Risk	HBsAg+	HBsAg-, anti-HBc+	Antiviral therapy	
High	Chemotherapy, anti- CD20 or anti-CD56, IST for transplantation, steroids in combination with other IST	Chemotherapy for hematologic malignancies, anti- CD20 or anti-CD56		 ✓ Start TDF or TAF ✓ Continue for 6 montl after stopping IST ✓ Monitor all patients
Moderate	Anti-TNF, maintenance low dose steroid, other IST without steroid	Chemotherapy for solid tumors, IST for transplantation, steroids in combination with other IST	Prophylaxis or on-demand (monitor)	✓ Monitor all patients
Low	Steroids alone for a few days	Anti-TNF, maintenance low dose steroid, other IST without steroid	No prophylaxis	✓ Monitor all patients